Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 17;15(1):237.
doi: 10.1186/s13098-023-01215-6.

LEP (G2548A-G19A) and ADIPOQ (T45G-G276T) gene polymorphisms are associated with markers for metabolic syndrome

Fred Luque Ortega #  1 , Alejandra Martínez Camberos #  2 , Martín Irigoyen Arredondo  2 , Noemí García Magallanes  3 , Eliakym Arámbula Meraz  4
Affiliations

LEP (G2548A-G19A) and ADIPOQ (T45G-G276T) gene polymorphisms are associated with markers for metabolic syndrome

Fred Luque Ortega et al. Diabetol Metab Syndr. .

Abstract

Background and aims: There is a link between genetics with metabolic balance and adiposity homeostasis on metabolic syndrome (MetS). Polymorphism in adipokine genes such as leptin and adiponectin may play an important role in its development. This study aimed to determine the association of the individual and general components of MetS with genetic alterations in LEP (rs7799039 and rs2167270) and ADIPOQ (rs1501299 and rs2241766) genes in the Mexican population.

Methods and results: The polymorphisms of the LEP gene rs7799039 and rs2167270, together with rs1501299 and rs2241766 polymorphisms of the ADIPOQ gene were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) on 328 individuals (n = 131 MetS). The rs7799039 under the recessive inheritance model was found to be associated with increased risk of MetS (OR = 2.16, 95% CI = 1.06-4.37), dyslipidemia (OR = 7.97, 95% CI = 2.17-29.36), low HDL (OR = 7.01, 95% CI = 1.65-29.71) and hypertension (OR = 13.02, 95% CI = 1.76-96.44); the heterozygote demonstrate a protective effect on MetS (OR = 0.48, 95% CI = 0.28-0.88) and diabetes (OR = 0.09, 95% CI = 0.02-0.53) under the over the dominant model. Haplotype analysis showed linkage disequilibrium between the SNPs of ADIPOQ rs1501299/rs2241766, and their association as risk factors for low HDL and hypertension.

Conclusion: The association of rs7799039 with the presence of MetS, suggests a risk factor for the development of dyslipidemia, as well as its heterozygous as a protective factor for DM. There is a linkage disequilibrium between the SNPs of ADIPOQ.

Keywords: ADIPOQ; Haplotype; LEP; Metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Linkage disequilibrium plot showing the position of LEP (rs7799039 and rs2167270) and ADIPOQ (rs2241766 and rs1501299) polymorphism and pair-wise D’ values observed in the study population concerning MetS; analysis by HaploView software
See this image and copyright information in PMC

References

    1. Gouveia ÉR, Gouveia BR, Marques A, Peralta M, França C, Lima A, et al. Predictors of metabolic syndrome in adults and older adults from Amazonas, Brazil. Int J Environ Res Public Health. 2021;18(3):1303. doi: 10.3390/ijerph18031303. - DOI - PMC - PubMed
    1. Wang Q, Ren D, Bi Y, Yuan R, Li D, Wang J, et al. Association and functional study between ADIPOQ and metabolic syndrome in elderly Chinese Han population. Aging. 2020;12(24):25819–27. doi: 10.18632/aging.104203. - DOI - PMC - PubMed
    1. Reina SA, Llabre MM, Vidot DC, Isasi CR, Perreira K, Carnethon M, et al. Metabolic syndrome in hispanic youth: results from the Hispanic Community Children’s Health Study/Study of latino youth. Metab Syndr Relat Disord. 2017;15(8):400–6. doi: 10.1089/met.2017.0054. - DOI - PMC - PubMed
    1. Hopkins JL, Hopkins PN, Brinton EA, Adams TD, Davidson LE, Nanjee MN, et al. Expression of metabolic syndrome in women with severe obesity. Metab Syndr Relat Disord. 2017;15(6):283–90. doi: 10.1089/met.2016.0116. - DOI - PMC - PubMed
    1. Löffler MC, Betz MJ, Blondin DP, Augustin R, Sharma AK, Tseng YH, et al. Challenges in tackling energy expenditure as obesity therapy: from preclinical models to clinical application. Mol Metab. 2021;51:101237. doi: 10.1016/j.molmet.2021.101237. - DOI - PMC - PubMed

LinkOut - more resources